Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R L Capizzi

Showing results (1-10 of 127) with videos related to

Pageof 13
Sort By:
Current Opinion in Oncology|February 1, 1990
Leukemia: experimental and preclinical studiesR L Capizzi
Cancer Treatment Reports|January 1, 1981
Asparaginase-methotrexate in combination chemotherapy: schedule-dependent differential effects on normal versus neoplastic cellsR L Capizzi
Seminars in Oncology|June 1, 1977
The place of pharmacology in cancer medicineR L Capizzi
Oncology (Williston Park, N.Y.)|October 1, 1989
More on the treatment of relapsed acute myeloid leukemiaR L Capizzi
Seminars in Oncology|May 29, 1999
Recent developments and emerging options: the role of amifostine as a broad-spectrum cytoprotective agentR L Capizzi
Seminars in Oncology|May 29, 1999
The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostineR L Capizzi
British Medical Journal|December 25, 1971
Wegener's granulomatosisR L Capizzi
Bone Marrow Transplantation|January 1, 1989
New cytarabine analogsR L Capizzi
Seminars in Oncology|May 29, 1999
Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspectsR L Capizzi
European Journal of Cancer (Oxford, England : 1990)|January 1, 1996
The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol)R L Capizzi
Pageof 13

Showing results (1-10 of 127) with videos related to

Sort By:
Pageof 13
Current Opinion in Oncology|February 1, 1990
Leukemia: experimental and preclinical studiesR L Capizzi
Cancer Treatment Reports|January 1, 1981
Asparaginase-methotrexate in combination chemotherapy: schedule-dependent differential effects on normal versus neoplastic cellsR L Capizzi
Seminars in Oncology|June 1, 1977
The place of pharmacology in cancer medicineR L Capizzi
Oncology (Williston Park, N.Y.)|October 1, 1989
More on the treatment of relapsed acute myeloid leukemiaR L Capizzi
Seminars in Oncology|May 29, 1999
Recent developments and emerging options: the role of amifostine as a broad-spectrum cytoprotective agentR L Capizzi
Seminars in Oncology|May 29, 1999
The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostineR L Capizzi
British Medical Journal|December 25, 1971
Wegener's granulomatosisR L Capizzi
Bone Marrow Transplantation|January 1, 1989
New cytarabine analogsR L Capizzi
Seminars in Oncology|May 29, 1999
Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspectsR L Capizzi
European Journal of Cancer (Oxford, England : 1990)|January 1, 1996
The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol)R L Capizzi
Pageof 13